General anesthesia administeredthrough inhalation route is categorized as IH anesthetics and is used formaintaining sedative stage during surgical procedure. IH drugs are preferredfor pediatric and geriatric surgery.
The global GeneralAnesthesia Drugs Market is estimated to account for US$ 5999.7 Mn in termsof value by the end of 2027.
Global General Anesthesia DrugsMarket: Drivers
Increasing prevalence of chronicrenal disease (CRD) is expected to boost growth of the global GeneralAnesthesia Drugs market over the forecast period. For instance, according toEuropean Renal Association – European Dialysis and Transplant Association’s datain 2018, over 850 million people worldwide have some form of kidney disease
Global General Anesthesia DrugsMarket: Opportunities
Increasing R&D in generalanesthesia is expected to offer to offer lucrative growth opportunities formarket players. For instance, in October 2019, a study published in the Journalof the American Medical Association (JAMA) by researchers from AarhusUniversity Hospital found that the use of protocol-based general anaesthesia inacute ischaemic stroke patients undergoing thrombectomy was significantlyassociated with less disability at three-months, compared with proceduralsedation.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/524
Global General Anesthesia DrugsMarket: Restraints
However, lack of skilledanesthetists and nurse anaesthetist is expected to hamper growth of the globalGeneral Anesthesia Drugs market.
Key Takeaways:
The Propofol segment in theglobal General Anesthesia Drugs market was valued at US$ 1,300.6 Mn in 2018 andis expected to reach US$ 2127.9 Mn by 2025 at a CAGR of 5.7% during theforecast period.The growth of the segment is attributed to increasing incidenceand prevalence of chronic diseases.
Market Trends
Key players in the market arefocused on product development and approval to expand their product portfolio.For instance, in October 2019, SunGen Pharmaceuticals, a privately heldspecialty pharmaceutical company, received its eighth ANDA approval from the USFood and Drug Administration (FDA) for Lidocaine Ointment USP used forproduction of anesthesia of accessible mucous membranes of the oropharynx.
Use of ketamine has increased asa pain management alternative due to the opioid epidemic in the U.S. However,use of ketamine is also associated with side effects such as hallucinations andvisual disturbances.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/general-anesthesia-drugs-market-524
Global General Anesthesia DrugsMarket: Competitive Landscape
Major players operating in theglobal General Anesthesia Drugs market include, Baxter International Inc.,AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA,and Hospira Inc.
Global General Anesthesia DrugsMarket: Key Developments
Key players in the market arefocused on adopting partnership strategies to expand their product portfolio.For instance, in December 2019, Nephron Pharmaceuticals Corporation partneredwith National Medical Products Inc. to offers patients quality care through virtuallypain-free anesthetics.
Key players in the market arefocused on adopting MA& strategies to expand their product portfolio. Forinstance, in November 2019, Sandoz, the generics unit of Novartis, acquiredAspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings to expandits presence in Asia Pacific. Aspen offers off-patent branded medicines with afocus on anesthetics and specialty brands.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/524
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
